J. Stern & Co. LLP Makes New $2.36 Million Investment in Intuitive Surgical, Inc. $ISRG

Key Points

• J. Stern & Co. LLP has acquired 4,772 shares of Intuitive Surgical, Inc. for approximately $2,363,000, making it the firm's 29th largest holding.
• Multiple institutional investors, including AlphaCore Capital LLC and Second Line Capital LLC, have recently increased their stakes in Intuitive Surgical, with institutional ownership now at 83.64%.
• Analysts have raised price targets for Intuitive Surgical, with an average price target of $595.95, and most analyst ratings falling within the "Buy" to "Hold" categories.

J. Stern & Co. LLP purchased a new position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,772 shares of the medical equipment provider's stock, valued at approximately $2,363,000. Intuitive Surgical comprises 0.2% of J. Stern & Co. LLP's investment portfolio, making the stock its 29th biggest holding.

Other large investors have also modified their holdings of the company. Parvin Asset Management LLC purchased a new stake in shares of Intuitive Surgical during the fourth quarter worth approximately $26,000. Chilton Capital Management LLC raised its stake in shares of Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares during the last quarter. Global Financial Private Client LLC raised its stake in shares of Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after purchasing an additional 38 shares during the last quarter. Elite Financial Inc. purchased a new stake in shares of Intuitive Surgical during the first quarter worth approximately $26,000. Finally, LFA Lugano Financial Advisors SA purchased a new stake in shares of Intuitive Surgical during the first quarter worth approximately $30,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Zacks Research cut Intuitive Surgical from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. UBS Group increased their price objective on Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a research report on Wednesday, July 23rd. Wells Fargo & Company increased their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a research report on Wednesday, July 23rd. Citigroup reiterated a "buy" rating and issued a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Finally, Evercore ISI increased their price objective on Intuitive Surgical from $470.00 to $550.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Thirteen research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and a consensus price target of $595.95.

Intuitive Surgical Stock Up 0.6%

Shares of ISRG traded up $2.69 during trading hours on Thursday, reaching $473.84. 1,548,672 shares of the company traded hands, compared to its average volume of 1,988,124. The stock has a market capitalization of $169.86 billion, a PE ratio of 66.09, a price-to-earnings-growth ratio of 4.94 and a beta of 1.59. Intuitive Surgical, Inc. has a fifty-two week low of $425.00 and a fifty-two week high of $616.00. The stock has a fifty day simple moving average of $501.17 and a 200 day simple moving average of $518.82.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%.The business's revenue for the quarter was up 21.4% compared to the same quarter last year. During the same quarter last year, the company earned $1.78 earnings per share. Research analysts predict that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the sale, the executive vice president directly owned 353 shares of the company's stock, valued at approximately $173,845.44. This trade represents a 92.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total value of $121,631.76. Following the completion of the sale, the senior vice president directly owned 907 shares in the company, valued at approximately $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 15,839 shares of company stock valued at $7,896,972. Insiders own 0.70% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.